CTNNB1 and neoplasm: Thus, increased type I/II IFNs released from the immune compartment (likely from T cells, macrophages, and dying tumor cells) following LNP-CTNNB1 treatment, engage with macrophages in the TIME milieu, and in part contribute towards polarizing them towards a pro-inflammatory anti-tumor phenotype.